Due to the efficacy in reducing HbA1c, accompanied by a weight loss effect, low risk of hypoglycemia, and ease of use (simple titration plan and once-daily or even once-weekly administration), the ADA/EASD Guideline recommends to preferentially use GLP-1 RAs in T2D patients before insulin therapy [3,4]. The gene discussed is INS; the disease is type 2 diabetes mellitus.